The frequency of protease and reverse transcriptase (RT) gene mutations was determined in
HIV-1 strains from 153 patients entering the CPCRA 046 (GART) study who were failing …

The reverse transcriptase (RT) and protease genes from 12 human immunodeficiency virus
type 2 (HIV-2)-infected individuals who had been exposed to antiretroviral drugs for longer …

Baseline genotype resistance analysis was carried out in 48 adults with primary HIV‐1
infection between 1995 and 1998 before starting early combination therapy. Seventeen …

High-density oligonucleotide arrays were used to determine the sequence of the protease
(PR) and reverse transcriptase (RT) genes of human immunodeficiency virus type 1 isolates …

Although protease inhibitors (PIs) have dramatically improved outcomes in HIV-infected
patients, half still fail treatment with PI-based combination therapy. Genetic pressure from …

HIV-1 resistance to protease inhibitors (PIs) is characterized by extensive cross-resistance
within this drug class. Some PIs, however, appear less affected by cross-resistance and are …

The objective was to study the persistence of drug resistance mutations detected earlier at
virological failure during second or third line antiretroviral therapy. Therefore, in HIV‐1 …

During its spread among humans, HIV-1 has developed an extraordinary degree of genetic
diversity. The pol region encoding for viral enzymes such as the reverse transcriptase and …

Objective To assess the prevalence of mutations in the reverse-transcriptase (RT) and
protease (PR) region in a cohort of chronically-infected HIV-positive patients requiring highly …

Progress in understanding antiretroviral resistance has evolved rapidly in recent years.
Specific resistance mutations have been associated with virologic failure of different …